Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Obesity | Research

The effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world data

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Achieving an optimal glycemic control has been described to reduce the incidence of diabetes mellitus (DM) related complications. The association between comorbidities and glycemic control remains unclear. Our aim is to evaluate the effect of comorbidities on glycemic control in people living with DM.

Methods

A retrospective longitudinal study on data from the National Registry of Chronic Kidney Disease from 2014 to 2019 in Colombia. The outcome was poor glycemic control (PGC = HbA1c ≥7.0%). The association between each comorbidity (hypertension (HTN), chronic kidney disease (CKD) or obesity) and PGC was evaluated through multivariate mixed effects logistic regression models. The measures of effect were odds ratios (OR) and their 95% confidence intervals (CI). We also evaluated the main associations stratified by gender, insurance, and early onset diabetes as well as statistical interaction between each comorbidity and ethnicity.

Results

From 969,531 people at baseline, 85% had at least one comorbidity; they were older and mostly female. In people living with DM and CKD, the odds of having a PGC were 78% (OR: 1.78, CI 95%: 1.55-2.05) higher than those without CKD. Same pattern was observed in obese for whom the odds were 52% (OR: 1.52, CI 95%: 1.31-1.75) higher than in non-obese. Non-significant association was found between HTN and PGC. We found statistical interaction between comorbidities and ethnicity (afro descendant) as well as effect modification by health insurance and early onset DM.

Conclusions

Prevalence of comorbidities was high in adults living with DM. Patients with concomitant CKD or obesity had significantly higher odds of having a PGC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.PubMedCrossRef Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.PubMedCrossRef
2.
go back to reference Vargas-Uricoechea H, Casas-Figueroa LÁ. An epidemiologic analysis of diabetes in Colombia. Ann Glob Health. 2015;81:742–53.PubMedCrossRef Vargas-Uricoechea H, Casas-Figueroa LÁ. An epidemiologic analysis of diabetes in Colombia. Ann Glob Health. 2015;81:742–53.PubMedCrossRef
3.
go back to reference Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3–16.CrossRefPubMed Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3–16.CrossRefPubMed
4.
go back to reference Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? J Diabetes Complicat. 2018;32:911–5.CrossRef Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? J Diabetes Complicat. 2018;32:911–5.CrossRef
5.
go back to reference Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.PubMedCrossRef Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.PubMedCrossRef
6.
go back to reference Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.PubMedCrossRef Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.PubMedCrossRef
7.
go back to reference Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.PubMedCrossRef Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.PubMedCrossRef
8.
go back to reference Mannucci E, Monami M, Dicembrini I, Piselli A, Porta M. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Investig. 2014;37:477–95.CrossRef Mannucci E, Monami M, Dicembrini I, Piselli A, Porta M. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Investig. 2014;37:477–95.CrossRef
9.
go back to reference De Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: Data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.CrossRef De Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: Data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.CrossRef
10.
go back to reference Smalls BL, Ritchwood TD, Bishu KG, Egede LE. Racial/ethnic differences in glycemic control in older adults with type 2 diabetes: United States 2003–2014. Int J Environ Res Public Health. 2020;17:950.PubMedCentralCrossRef Smalls BL, Ritchwood TD, Bishu KG, Egede LE. Racial/ethnic differences in glycemic control in older adults with type 2 diabetes: United States 2003–2014. Int J Environ Res Public Health. 2020;17:950.PubMedCentralCrossRef
11.
go back to reference Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complicat. 2010;24:382–91.CrossRef Suh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complicat. 2010;24:382–91.CrossRef
12.
go back to reference Chetoui A, Kaoutar K, Elmoussaoui S, Boutahar K, El Kardoudi A, Chigr F, et al. Prevalence and determinants of poor glycaemic control: a cross-sectional study among Moroccan type 2 diabetes patients. Int Health. 2020;00:1–8. Chetoui A, Kaoutar K, Elmoussaoui S, Boutahar K, El Kardoudi A, Chigr F, et al. Prevalence and determinants of poor glycaemic control: a cross-sectional study among Moroccan type 2 diabetes patients. Int Health. 2020;00:1–8.
13.
go back to reference Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1243–52.PubMedCrossRef Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1243–52.PubMedCrossRef
14.
go back to reference Luijks H, Biermans M, Bor H, van Weel C, Lagro-Janssen T, de Grauw W, et al. The effect of comorbidity on glycemic control and systolic blood pressure in type 2 diabetes: a cohort study with 5 year follow-up in primary care. PLoS One. 2015;10:e0138662.PubMedPubMedCentralCrossRef Luijks H, Biermans M, Bor H, van Weel C, Lagro-Janssen T, de Grauw W, et al. The effect of comorbidity on glycemic control and systolic blood pressure in type 2 diabetes: a cohort study with 5 year follow-up in primary care. PLoS One. 2015;10:e0138662.PubMedPubMedCentralCrossRef
15.
go back to reference Bralić Lang V, Bergman MB. Prevalence of comorbidity in primary care patients with type 2 diabetes and its association with elevated HbA1c: a cross-sectional study in Croatia. Scand J Prim Health Care. 2016;34:66–72.PubMedPubMedCentralCrossRef Bralić Lang V, Bergman MB. Prevalence of comorbidity in primary care patients with type 2 diabetes and its association with elevated HbA1c: a cross-sectional study in Croatia. Scand J Prim Health Care. 2016;34:66–72.PubMedPubMedCentralCrossRef
16.
go back to reference Hudon C. Comorbidity and glycemia control among patients with type 2 diabetes in primary care. Diabetes Metab Syndr Obes Targets Ther. 2008;1:33–7.CrossRef Hudon C. Comorbidity and glycemia control among patients with type 2 diabetes in primary care. Diabetes Metab Syndr Obes Targets Ther. 2008;1:33–7.CrossRef
17.
go back to reference Almetwazi M, Alwhaibi M, Balkhi B, Almohaini H, Alturki H, Alhawassi T, et al. Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J. 2019;27:384–8.PubMedCrossRef Almetwazi M, Alwhaibi M, Balkhi B, Almohaini H, Alturki H, Alhawassi T, et al. Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J. 2019;27:384–8.PubMedCrossRef
18.
go back to reference Alzaheb R, Altemani A. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes Targets Ther. 2018;11:15–21.CrossRef Alzaheb R, Altemani A. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes Targets Ther. 2018;11:15–21.CrossRef
25.
go back to reference American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S66–76.CrossRef American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S66–76.CrossRef
27.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef
28.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
29.
go back to reference Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS®. SAS Glob Forum Stat Data Anal. 2012;335:1–6. Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS®. SAS Glob Forum Stat Data Anal. 2012;335:1–6.
31.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–115.CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–115.CrossRef
32.
go back to reference Sosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull World Health Organ. 2009;87:512–9.PubMedPubMedCentralCrossRef Sosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull World Health Organ. 2009;87:512–9.PubMedPubMedCentralCrossRef
33.
go back to reference Zhang X, McKeever Bullard K, Gregg EW, Beckles GL, Williams DE, Barker LE, et al. Access to health care and control of ABCS of diabetes. Diabetes Care. 2012;35:1566–71.PubMedPubMedCentralCrossRef Zhang X, McKeever Bullard K, Gregg EW, Beckles GL, Williams DE, Barker LE, et al. Access to health care and control of ABCS of diabetes. Diabetes Care. 2012;35:1566–71.PubMedPubMedCentralCrossRef
35.
go back to reference Copur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, et al. Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. J Diabetes Complicat. 2020;34:107707.CrossRef Copur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, et al. Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. J Diabetes Complicat. 2020;34:107707.CrossRef
36.
go back to reference De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi annals initiative. Nephrol Dial Transplant. 2015;30:1526–33.PubMedCrossRef De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi annals initiative. Nephrol Dial Transplant. 2015;30:1526–33.PubMedCrossRef
37.
go back to reference Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complicat. 2016;30:212–20.CrossRef Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complicat. 2016;30:212–20.CrossRef
38.
go back to reference Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29:2167–77.PubMedCrossRef Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29:2167–77.PubMedCrossRef
39.
go back to reference Hill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84–94.PubMedCrossRef Hill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84–94.PubMedCrossRef
40.
go back to reference Kuo I-C, Lin HY-H, Niu S-W, Hwang D-Y, Lee J-J, Tsai J-C, et al. Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney Disease. Sci Rep. 2016;6:20028.PubMedPubMedCentralCrossRef Kuo I-C, Lin HY-H, Niu S-W, Hwang D-Y, Lee J-J, Tsai J-C, et al. Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney Disease. Sci Rep. 2016;6:20028.PubMedPubMedCentralCrossRef
41.
go back to reference Esteghamati A, Ismail-Beigi F, Khaloo P, Moosaie F, Alemi H, Mansournia MA, et al. Determinants of glycemic control: phase 2 analysis from nationwide diabetes report of National Program for prevention and control of diabetes (NPPCD-2018). Prim Care Diabetes. 2020;14:222–31.PubMedCrossRef Esteghamati A, Ismail-Beigi F, Khaloo P, Moosaie F, Alemi H, Mansournia MA, et al. Determinants of glycemic control: phase 2 analysis from nationwide diabetes report of National Program for prevention and control of diabetes (NPPCD-2018). Prim Care Diabetes. 2020;14:222–31.PubMedCrossRef
42.
go back to reference Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:1295–305.PubMedCrossRef Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:1295–305.PubMedCrossRef
43.
go back to reference Lerman-Garber I, Aguilar-Salinas C, Tusié-Luna T, Velásquez D, Lobato-Valverde M, Osornio-Flores M, et al. Diabetes tipo 2 de inicio temprano. Experiencia en una institución de tercer nivel de atención médica. Gac Med Mex. 2010;146:179–84.PubMed Lerman-Garber I, Aguilar-Salinas C, Tusié-Luna T, Velásquez D, Lobato-Valverde M, Osornio-Flores M, et al. Diabetes tipo 2 de inicio temprano. Experiencia en una institución de tercer nivel de atención médica. Gac Med Mex. 2010;146:179–84.PubMed
44.
go back to reference Bo A, Thomsen RW, Nielsen JS, Nicolaisen SK, Beck-Nielsen H, Rungby J, et al. Early-onset type 2 diabetes: age gradient in clinical and behavioural risk factors in 5115 persons with newly diagnosed type 2 diabetes-results from the DD2 study. Diabetes Metab Res Rev. 2018;34:e2968.CrossRef Bo A, Thomsen RW, Nielsen JS, Nicolaisen SK, Beck-Nielsen H, Rungby J, et al. Early-onset type 2 diabetes: age gradient in clinical and behavioural risk factors in 5115 persons with newly diagnosed type 2 diabetes-results from the DD2 study. Diabetes Metab Res Rev. 2018;34:e2968.CrossRef
45.
go back to reference Gopalan A, Mishra P, Alexeeff SE, Blatchins MA, Kim E, Man A, et al. Initial glycemic control and care among younger adults diagnosed with type 2 diabetes. Diabetes Care. 2020;43:975–81.PubMedPubMedCentralCrossRef Gopalan A, Mishra P, Alexeeff SE, Blatchins MA, Kim E, Man A, et al. Initial glycemic control and care among younger adults diagnosed with type 2 diabetes. Diabetes Care. 2020;43:975–81.PubMedPubMedCentralCrossRef
46.
go back to reference Badedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors associated with long-term control of type 2 diabetes mellitus. J Diabetes Res. 2016;2016:2109542.PubMedPubMedCentralCrossRef Badedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors associated with long-term control of type 2 diabetes mellitus. J Diabetes Res. 2016;2016:2109542.PubMedPubMedCentralCrossRef
47.
go back to reference Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16:264–75.PubMed Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16:264–75.PubMed
48.
go back to reference Gil J, Sicras-Mainar A, Zucchelli E. Uncontrolled diabetes and health care utilisation: panel data evidence from Spain. Eur J Health Econ. 2018;19:785–95.PubMedCrossRef Gil J, Sicras-Mainar A, Zucchelli E. Uncontrolled diabetes and health care utilisation: panel data evidence from Spain. Eur J Health Econ. 2018;19:785–95.PubMedCrossRef
49.
go back to reference Mata-Cases M, Rodríguez-Sánchez B, Mauricio D, Real J, Vlacho B, Franch-Nadal J, et al. The association between poor glycemic control and health care costs in people with diabetes: a population-based study. Diabetes Care. 2020;43:751–8.PubMedCrossRef Mata-Cases M, Rodríguez-Sánchez B, Mauricio D, Real J, Vlacho B, Franch-Nadal J, et al. The association between poor glycemic control and health care costs in people with diabetes: a population-based study. Diabetes Care. 2020;43:751–8.PubMedCrossRef
Metadata
Title
The effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world data
Publication date
01-12-2021
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00791-w

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.